Babylon launches AI-powered healthcare app to help New Yorkers

Babylon is partnering with Mount Sinai Health Partners to bring its AI-powered digital healthcare solution to New York. The smartphone app is available 24/7 and includes live chat, virtual doctor consultations and a new COVID-19 Care Assistant, which provides users with updated information and statistics related to the pandemic.

Babylon chose to launch in New York at this time to help the city as it deals with challenges—including crowded emergency rooms, misinformation and patient anxiety—related to COVID-19.

“At a time that one of the greatest cities in the world is going through one of its worst public health crises, our relationship brings the brilliant services of Mount Sinai Health Partners together with the unique global expertise of Babylon, to give eligible insurance plan members in the city access for their primary healthcare needs, wherever they are and whenever they need it,” Ali Parsa, PhD, CEO and founder of Babylon, said in a prepared statement.

“Babylon, a leader in convenient and accessible digital health care services, is a valuable addition to our high-performing primary care network,” added Robert W. Fields, MD, MHA, chief medical officer for Mount Sinai Health Partners. “New York is the epicenter of the COVID-19 pandemic and more than ever the need to engage with our patients in their homes has become an essential part of healthcare. Having Babylon in our network also strengthens our capacity in this area to serve our patients at the highest level.”

Babylon’s services are now available in New York, California and Missouri—the goal is to eventually provide care in all 50 states.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.